INT-767 is primarily investigated for its therapeutic potential in metabolic and liver-related disorders. It acts as a dual agonist for farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5), making it effective in regulating bile acid homeostasis, glucose metabolism, and inflammation. In preclinical studies, it has shown promise in treating non-alcoholic steatohepatitis (NASH) by reducing liver inflammation, fibrosis, and lipid accumulation. Additionally, it has been explored for its role in improving insulin sensitivity and managing type 2 diabetes. Its anti-inflammatory properties also make it a candidate for addressing inflammatory bowel disease (IBD) and other immune-related conditions. Research continues to evaluate its efficacy and safety in clinical applications.